SCHEMBL4811754

SCHEMBL4811754

CCn1nc(Cc2ccc(C(=O)NCc3cccnc3)cc2-c2ccc(C)cc2C(=O)O)c2ccc(C(=N)N)cc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 4/20 0.46
PKM P14618 2/20 0.42
PPARG P37231 1/20 0.42
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 2/20 0.40
ALDH1A1 P00352 2/20 0.40
GAA P10253 1/20 0.40
TSHR P16473 1/20 0.40
BLM P54132 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
CYP2C19 P33261 1/20 0.39
F2 P00734 1/20 0.39
F10 P00742 1/20 0.39
F7 P08709 1/20 0.39
F3 P13726 1/20 0.39
MMP13 P45452 1/20 0.39
USP2 O75604 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
ROCK2 O75116 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4813356 0.93 ROCK2 (0.45) PIK3CAPKMPPARGALDH1A1GAA
SCHEMBL4810537 0.91 ROCK2 (0.46) PIK3CACYP1A2CYP3A4ALDH1A1GAA
SCHEMBL4815003 0.89 ALDH1A1 (0.38) PIK3CACYP1A2CYP3A4ALDH1A1CYP2C19
SCHEMBL4812866 0.87 PIK3CA (0.44) PIK3CAPKMPPARGCYP1A2CYP3A4
SCHEMBL4809282 0.86 P2RX3 (0.43) CYP1A2ALDH1A1CYP2C19F2F10
SCHEMBL4816068 0.82 SLC22A12 (0.39) F2F10F7F3
SCHEMBL4812948 0.80 F2 (0.43) PPARGCYP1A2CYP3A4ALDH1A1GAA
SCHEMBL4807167 0.79 F10 (0.42) PPARGALDH1A1GAATSHRL3MBTL1
SCHEMBL4811035 0.79 ROCK2 (0.47) PIK3CACYP1A2CYP3A4ALDH1A1GAA
SCHEMBL4807591 0.78 PIK3CA (0.39) PIK3CACYP1A2CYP3A4ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7417063-B2 Bicyclic heterocycles useful as serine protease inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-08-26 US claimed
US-20050228000-A1 of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent BRISTOL-MYERS SQUIBB COMPANY 2005-10-13 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228000-A1 of the coagulation cascade or contact activation system: thrombin, factor Xa, factor XIa, factor IXa, factor VIIa or plasma kallikrein; e.g. -(6-carbamimidoyl-1H-indol-3-ylmethyl)-4-methoxy-biphenyl-2-carboxylic acid; anticoagulant, antiinflammatory agent F12, F11, F2 PIK3CA 555/4885PKM 1250/4885PPARG 3726/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.